Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

10 сен 2021 09:00:00 Источник Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

05 авг 2021 16:01:01 Источник Nasdaq GlobeNewswire

Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021

29 июл 2021 16:05:01 Источник Nasdaq GlobeNewswire

Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

06 июл 2021 08:37:42 Источник Nasdaq GlobeNewswire

Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA

25 июн 2021 09:00:00 Источник Nasdaq GlobeNewswire

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

23 июн 2021 09:00:01 Источник Nasdaq GlobeNewswire

Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

04 июн 2021 09:05:00 Источник Nasdaq GlobeNewswire

Y-mAbs Announces Update on Omburtamab for DIPG

04 июн 2021 09:00:00 Источник Nasdaq GlobeNewswire

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

19 май 2021 16:01:00 Источник Nasdaq GlobeNewswire

Y-mAbs Announces Update on SADA Technology

13 май 2021 09:00:02 Источник Nasdaq GlobeNewswire

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

06 май 2021 16:01:02 Источник Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021

29 апр 2021 16:01:00 Источник Nasdaq GlobeNewswire

Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting

29 апр 2021 09:00:02 Источник Nasdaq GlobeNewswire

Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency

27 апр 2021 16:01:00 Источник Nasdaq GlobeNewswire

Y-mAbs Provides Regulatory Update on Omburtamab   

20 апр 2021 09:00:01 Источник Nasdaq GlobeNewswire

Y-mAbs Announces GPA33-SADA Data Presented at AACR

12 апр 2021 09:00:00 Источник Nasdaq GlobeNewswire

Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments

25 фев 2021 16:01:00 Источник Nasdaq GlobeNewswire

Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

22 фев 2021 16:01:00 Источник Nasdaq GlobeNewswire

Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021

19 фев 2021 09:00:00 Источник Nasdaq GlobeNewswire

Y-mAbs Announces Pricing of Public Offering of Common Stock

17 фев 2021 19:14:43 Источник Nasdaq GlobeNewswire